Accommodating IOL's new design shows benefits

Results of a multicenter FDA clinical trial of a fourth-generation version of an accommodating IOL (crystalens HD-100, eyeonics/Bausch & Lomb) demonstrate that the lens provides excellent uncorrected visual acuity at all distances that exceeds those of previous versions and without causing loss of contrast sensitivity.

Related Videos
Related Content

American Academy of Ophthalmology rallies against expanding prior authorization to Medicare Fee For Services

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Optimizing vision outcomes and diabetic macular edema

March 30th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023

American Academy of Ophthalmology rallies against expanding prior authorization to Medicare Fee For Services

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Optimizing vision outcomes and diabetic macular edema

March 30th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023

American Academy of Ophthalmology rallies against expanding prior authorization to Medicare Fee For Services

March 30th 2023

Podcast: Talking about the anterior segment pipeline for 2023

March 29th 2023

Optimizing vision outcomes and diabetic macular edema

March 30th 2023

The importance of ocular health prior to cataract and refractive surgery

February 28th 2023

Early study shows cones in retinal degeneration, thought to be dormant, may retain visual function

March 29th 2023

Jumping into gene therapy with collaboration, innovation

March 29th 2023
© 2023 MJH Life Sciences

All rights reserved.